Impact of Chinese national centralized volume-based drug procurement policy on health costs and utilization: An interrupted time series analysis using panel data (2009–2022)
Yishi Jiang, Guangsheng Wan, Yufeng Shi, Guiping Pu, Xiaojun Shao · 2025
Read Impact of Chinese national centralized volume-based drug procurement policy on health costs and utilization: An interrupted time series analysis using panel data (2009–2022) by Yishi Jiang, Guangsheng Wan, Yufeng Shi, Guiping Pu, Xiaojun Shao (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12742737.txt.
Description
Yishi Jiang and co-authors report a 2025 study of China's central drug buying policy, in force nationwide since 2019. The policy pools demand to bargain drug prices down. Past work showed price drops, but system wide effects on cost and care use were less mapped.
The team used yearbook panel data from 2009 to 2022 and split the trend at the policy start. Outcomes covered cost per clinic and hospital visit, visit rates, and length of stay. At the switch point, cost per visit jumped up in the short run for both care types. A two stage pooled analysis then weighed how effects varied by region over the long term.
Catalog record
| CREATOR | Yishi Jiang, Guangsheng Wan, Yufeng Shi, Guiping Pu, Xiaojun Shao |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |